Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development
Jack Uetrecht(University of Toronto), Adrian M. Di Bisceglie(Saint Louis University), James W. Freston(University of Connecticut), Ethan Miller(The University of Texas MD Anderson Cancer Center), Niti Patel(Takeda (United States)), Mark Avigan, Robert J. Fontana(University of Michigan), Alexandre Kiazand(AstraZeneca (United States)), Arie Regev, Stephanie O. Omokaro(United States Food and Drug Administration), Gerd A. Kullak‐Ublick(University Hospital of Zurich), Hewei Li(Bristol-Myers Squibb (United States)), Karen Price(Purchase College), Meenal Patwardhan(AbbVie (United States)), Melanie J. Harrison(Bristol-Myers Squibb (United States)), John M Vierling, James H Lewis, Herbert L. Bonkovsky, Naga P Chalasani, Nonko Pehlivanov(Janssen (United States)), Paul B. Watkins(University of North Carolina at Chapel Hill), Syed Asif Haque(AstraZeneca (United States))
Cited by 0
Related Papers
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease†
|Hepatology|2008|865
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
|Gastroenterology|2015|799
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|726